key: cord-0910407-iduq6kte
authors: Wiwanitkit, Viroj
title: Ivermectin and COVID-19
date: 2021-04-21
journal: Malays J Med Sci
DOI: 10.21315/mjms2021.28.2.17
sha: 026d921273e34f8a4956672b6230156ed0a1f229
doc_id: 910407
cord_uid: iduq6kte

nan

(1) discussed 'the potential for ivermectin to be used as a therapeutic option in COVID-19. In fact, many classic drugs are proposed as potential therapeutic agents against COVID-19. Hydroxychloroquine is a good example (2) . Ivermectin, is another potential drug for COVID-19 therapy. In some countries such as India, ivermectin is used for mass chemoprophylaxis of lymphatic filariasis. Nevertheless, there is a high incidence of COVID-19 in the area that ivermectin is routinely used. Therefore, a standard prophylactic dose of ivermectin might not be useful for COVID-19 therapy. Since ivermectin is a classic drug with safety evidence, further trials on ivermectin against COVID-19 are recommended. In some countries such as India, ivermectin is used for mass chemoprophylaxis of lymphatic filariasis (3).

Ivermectin: potential role as repurposed drug for COVID-19

Evidence of protective effect of hydroxychloroquine on COVID-19

The story of lymphatic filariasis elimination as a public health problem from Yemen

None.

None.

None.

Professor Viroj Wiwanitkit PhD, MD (Chulalongkorn University, Bangkok Thailand) DY Patil University, Lohgaon, Airport Rd, Charholi Budruk, Pune, Maharashtra 412105, India. Tel: +91 20 6711 6400 E-mail: wviroj@yahoo.com